Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMadariaga, Leire
dc.contributor.authorCastaño, Alejandro
dc.contributor.authorMartínez, Rosa
dc.contributor.authorAguayo Calcena, Anibal
dc.contributor.authorCastaño, Luis
dc.contributor.authorAriceta Iraola, Gema
dc.date.accessioned2019-08-01T11:48:49Z
dc.date.available2019-08-01T11:48:49Z
dc.date.issued2018-11-13
dc.identifier.citationMadariaga L, García-Castaño A, Ariceta G, Martínez-Salazar R, Aguayo A, Castaño L, et al. Variable phenotype in HNF1B mutations: extrarenal manifestations distinguish affected individuals from the population with congenital anomalies of the kidney and urinary tract. Clin Kidney J. 2019;12(3):373–9.
dc.identifier.issn2048-8505
dc.identifier.urihttps://hdl.handle.net/11351/4231
dc.descriptionCAKUT; HNF1B; MODY
dc.description.abstractBACKGROUND: Mutations in hepatocyte nuclear factor 1B (HNF1B) have been associated with congenital anomalies of the kidney and urinary tract (CAKUT) in humans. Diabetes and other less frequent anomalies have also been described. Variable penetrance and intrafamilial variability have been demonstrated including severe prenatal phenotypes. Thus, it is important to differentiate this entity from others with similar clinical features and perform confirmatory molecular diagnosis. METHODS: This study reports the results of HNF1B screening in a cohort of 60 patients from 58 unrelated families presenting with renal structural anomalies and/or non-immune glucose metabolism alterations, and other minor features suggesting HNF1B mutations. RESULTS: This study identified a pathogenic variant in 23 patients from 21 families. The most frequent finding was bilateral cystic dysplasia or hyperechogenic kidneys (87% of patients). Sixty percent of them also fulfilled the criteria for impaired glucose metabolism, and these were significantly older than those patients with an HNF1B mutation but without diabetes or prediabetes (14.4 versus 3.3 years, P < 0.05). Furthermore, patients with HNF1B mutations had higher frequency of pancreatic structural anomalies and hypomagnesaemia than patients without mutations (P < 0.001 and P = 0.003, respectively). Hyperuricaemia and increased liver enzymes were detected in some patients as well. CONCLUSIONS: Renal anomalies found in patients with HNF1B mutations are frequently unspecific and may resemble those found in other renal pathologies (CAKUT, ciliopathies). Active searching for extrarenal minor features, especially pancreatic structural anomalies or hypomagnesaemia, could support the indication for molecular diagnosis to identify HNF1B mutations.
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.ispartofseriesClinical Kidney Journal;12(3)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAparell genitourinari - Malalties
dc.subjectGlucosa - Metabolisme
dc.subjectMalalties congènites
dc.subjectProteïnes
dc.subjectMutació (Biologia)
dc.subject.meshUrogenital Abnormalities
dc.subject.meshGlucose Metabolism Disorders
dc.subject.mesh/genetics
dc.subject.meshHepatocyte Nuclear Factor 1-beta
dc.subject.meshMutation
dc.titleVariable phenotype in HNF1B mutations: extrarenal manifestations distinguish affected individuals from the population with congenital anomalies of the kidney and urinary tract
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1093/ckj/sfy102
dc.subject.decsanomalías urogenitales
dc.subject.decstrastornos del metabolismo de la glucosa
dc.subject.decs/genética
dc.subject.decsfactor nuclear 1-beta del hepatocito
dc.subject.decsmutación
dc.relation.publishversionhttps://academic.oup.com/ckj/article/12/3/373/5181379
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Madariaga L] Pediatric Nephrology Department, Cruces University Hospital, Barakaldo, Spain. Universidad del País Vasco, Barakaldo, Spain. Biocruces Health Research Institute, Barakaldo, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain. [García-Castaño A] Biocruces Health Research Institute, Barakaldo, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain. [Ariceta G] Servei de Nefrologia Pediàtrica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Martínez-Salazar R, Aguayo A] Biocruces Health Research Institute, Barakaldo, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain. [Castaño L] Pediatric Nephrology Department, Cruces University Hospital, Barakaldo, Spain. Universidad del País Vasco, Barakaldo, Spain. Biocruces Health Research Institute, Barakaldo, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
dc.identifier.pmid31198537
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record